Your Questions, Answered
We’ve assembled the most frequently asked questions about Eversense into one place. Got a question that you can’t find the answer to? Contact us.
The sensor has a silicone ring that contains a small amount of an anti-inflammatory drug (dexamethasone acetate). For more information regarding dexamethasone acetate please contact your health care professional.
If you are concerned that you may be experiencing an adverse effect, contact your health care professional.
The Eversense® E3 Sensor does not contain any natural rubber latex.
The Eversense® E3 CGM system will stop sending glucose readings after 180 days. To continue using Eversense®, you will need to have your current sensor removed and a new sensor inserted.
It is recommended to avoid areas with loose skin, scars, tattoos, nerves, or blood vessels that could be incised during the procedure.
This should only be done if directly instructed by customer care. The system will return to initialization phase after re-linking is complete.
The Eversense® E3 Smart Transmitter is a removable transmitter worn externally over the sensor. It wirelessly powers the sensor and collects glucose data via Near-Field Communication (NFC). It wirelessly sends glucose data (via Bluetooth) to the Eversense® Mobile App. It has a rechargeable battery and is warranted for one year.
Still have questions?
The Eversense team is dedicated and ready to provide the answers and support you need. Simply click the link below.
The Eversense® E3 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to 180 days in persons with diabetes age 18 and older. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time a day after day 21, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense E3 CGM System is a prescription device; patients should talk to their health care provider to learn more.
The Eversense® 365 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to one year in people (18 years and older) with diabetes. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are required for calibration one time a week after day 13, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense 365 CGM System is a prescription device; patients should talk to their health care provider to learn more.
For important safety information, see bit.ly/eversensesafety
Eversense, Eversense E3 Continuous Glucose Monitoring, Eversense 365 Continuous Glucose Monitoring, and the Eversense logo are trademarks of Senseonics, Incorporated. Ascensia, the Ascensia Diabetes Care logo are trademarks and/or registered trademarks of Ascensia Diabetes Care Holdings AG. All other trademarks are properties of their respective owners and are used solely for informative purposes. No relationship or endorsement should be inferred or implied.
Apple Watch® is a product of Apple, Inc., and may be separately purchased from an authorized Apple retailer. Apple Watch is not included with the Eversense CGM System. Android is a trademark of Google LLC.
PP-SENS-E3-GBL-0060